Brainsway Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Brainsway Ltd., a foreign private issuer, for the month of March 2026. The report, dated March 4, 2026, was signed by Hadar Levy, Chief Executive Officer. The filing incorporates by reference into the company's Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to disclose a specific corporate event rather than presenting periodic financial statements.
Material Changes and Corporate Events
The primary material event disclosed in this filing is the release of data validating Brainsway's SWIFT Deep Transcranial Magnetic Stimulation (TMS) technology. The company characterizes this as a "Landmark Data" release that begins a "New Era in Depression Treatment."
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, quantitative outlook, or detailed risk factors. Management commentary is limited to the announcement of the clinical data validation for the SWIFT Deep TMS system.
Investor Verification Checklist
- Verify the specific clinical trial data and statistical significance referenced in the "Landmark Data" announcement (Exhibit 99.1).
- Confirm the regulatory status of the SWIFT Deep TMS technology in key markets following this data release.
- Review the full text of the press release or presentation attached as Exhibit 99.1 for details on the "New Era in Depression Treatment."
- Check subsequent filings for any financial impact or revenue recognition related to this clinical milestone.